



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Corilagin

Cat. No.:	HY-N0462
CAS No.:	23094-69-1
Molecular Formula:	C ₂₇ H ₂₂ O ₁₈
Molecular Weight:	634.45
Target:	Reverse Transcriptase; Bacterial; Apoptosis; Autophagy
Pathway:	Anti-infection; Apoptosis; Autophagy
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (157.62 mM; Need ultrasonic)
H₂O : 5 mg/mL (7.88 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.5762 mL	7.8808 mL	15.7617 mL
	5 mM		0.3152 mL	1.5762 mL	3.1523 mL
	10 mM		0.1576 mL	0.7881 mL	1.5762 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 5.88 mg/mL (9.27 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of *Staphylococcus aureus* with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues^{[1][2][3]}.

In Vitro

Corilagin (0-50 μ M, 24 h) inhibits SGC7901 and BGC823 cell growth, and the cells became rounded^[2].
Corilagin (0-30 μ M, 24 h) induces SGC7901 and BGC823 cell apoptosis^[2].
Corilagin (0-30 μ M, 24 h) decreased the protein levels of procaspase-8, -9 and -3 and increases cleaved PARP in SGC7901 and BGC823 cell^[2].
Corilagin (0-30 μ M, 24 h) induces autophagy in SGC7901 and BGC823 cell (enhancement of acidic vesicles, increased the level of LC3II)^[2].
Corilagin (0-30 μ M, 24 h) induces ROS generation in SGC7901 and BGC823 cell^[2].
Corilagin (40 μ M, 24 or 48 h) induces G2 cell cycle arrest and apoptosis in Hey and SKOV3ip cells^[3].
Corilagin (0-80 μ M, 1-3 days) inhibits the secretion of TGF- β 1 in Hey, SKOV3ip and HO8910PM cells^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	SGC7901 and BGC823 cell
Concentration:	0, 10, 20, 30, 40 and 50 μ M
Incubation Time:	24 h
Result:	Inhibited cell proliferation in a concentration-dependent manner.

Western Blot Analysis^[2]

Cell Line:	SGC7901 and BGC823 cell
Concentration:	0, 10, 20, 30 μ M
Incubation Time:	24 h
Result:	Decreased the protein levels of procaspase-8, -9 and -3 and increased the level of cleaved PARP.

In Vivo

Corilagin (15 mg/kg, i.p., for 7 days) shows anti-tumor activity in Hep3B hepatocellular carcinoma^[4].
Corilagin (0-20 mg/kg, i.p.) prevents APAP-induced hepatotoxicity in mice^[5].
Corilagin (10 and 100 mg/kg, i.p.) ameliorates Bleomycin-induced pulmonary fibrosis in mice^[6].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hep3B hepatocellular carcinoma mouse model ^[4] .
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited tumor growth without toxic effects.

Animal Model:	APAP-induced hepatotoxicity in mice ^[5]
Dosage:	0, 1, 5, 10, 20 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased APAP-induced serum ALT level, hepatic myeloperoxidase (MPO) activity, cytokines (TNF- α , IL-1 β , and IL-6) production, malondialdehyde (MDA) activity, and ERK/JNK MAPK and NF- κ B protein expressions.

CUSTOMER VALIDATION

- Front Immunol. 2022 Jan 13;12:807509.
- Fitoterapia. 2023 Nov 10;172:105743.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Xu J, et al. Corilagin induces apoptosis, autophagy and ROS generation in gastric cancer cells in vitro. *Int J Mol Med*. 2019 Feb;43(2):967-979.
- [2]. Jia L, et al. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF- β signaling pathways. *BMC Complement Altern Med*. 2013 Feb 15;13:33.
- [3]. Hau DK, et al. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. *Phytomedicine*. 2010 Dec 15;18(1):11-5.
- [4]. Liu FC, et al. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF- κ B signaling pathway in a mouse model. *Am J Transl Res*. 2020 Sep 15;12(9):5597-5607.
- [5]. Wang Z, et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. *Int J Mol Sci*. 2014 May 30;15(6):9762-79.
- [6]. Li X, et al. Corilagin, a promising medicinal herbal agent. *Biomed Pharmacother*. 2018 Mar;99:43-50.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA